U.S. Food and Drug Administration
Pediatric Information -- Table II
Updated December 18, 1997
| |
Norvir
Abbott
ritonavir |
Viracept®
Agouron
nelfinavir |
| Pediatric
Dosage |
400
mg/m< bid not to exceed 600 mg bid |
20-30
mg/kg tid not to exceed 750 mg tid |
Pediatric
Dosage
Initiations/Adjustments |
Ritonavir
should be started at 250 mg/m<and increased every 2-3
days by 50 mg/m< twice daily.
If 400 mg/m< is not tolerated, the
highest tolerated dose should be used for maintenance
therapy in combination with nucleoside analogues.
|
-------- |
Pediatric
Dosage
Guidelines |
See Table A |
See Table B |
Pediatric
Age Range
Studied |
2-14
years pharmacokinetic study |
2-13
years pharmacokinetic study |
Pediatric
Mixing
Recommendations |
Oral
solution does not require mixing. Dose should be
administered using a calibrated dosing syringe. |
Oral
Powder may be mixed with a small amount of water, milk,
formula, soy formula, soy milk or dietary supplements.
Oral powder should not be reconstituted with water in its
original container. Acidic food or juice (e.g.orange
juice, apple juice or apple sauce) are not
recommended to be used with the Oral Powder
because it may result in bitter taste. |
Back | Next
Table of Contents
This article was provided by
U.S. Food and Drug Administration.
It is a part of the publication Protease Inhibitors Backgrounder.